- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Glycogen Synthase Deficiency
Total 9255 results
-
Moscow Regional Research and Clinical Institute...TerminatedGlycogen Synthase Kinase 3Russian Federation
-
Rigshospitalet, DenmarkUnknownCarbohydrate Metabolism, Inborn Errors | Metabolism, Inborn Errors | Lipid Metabolism, Inborn Errors | Glycogen Storage Disease Type II | Glycogen Storage Disease Type V | VLCAD Deficiency | Glycogen Storage Disease Type III | Phosphoglycerate Kinase Deficiency | Neutral Lipid Storage Disease | Carnitine... and other conditionsDenmark
-
DDC Clinic - Center for Special Needs ChildrenUnknownGM3 Synthase Deficiency
-
Polaris GroupCompletedArgininosuccinate Synthetase DeficientUnited States
-
Baylor College of MedicineChildren's National Research InstituteRecruitingOrnithine Transcarbamylase Deficiency | Urea Cycle Disorder | Carbamyl Phosphate Synthetase Deficiency | Argininosuccinic Aciduria | Hyperargininemia | Citrullinemia 1 | ARGI Deficiency | ASL Deficiency | ASS Deficiency | NAGS DeficiencyUnited States
-
Cytonet GmbH & Co. KGCompletedOrnithine Transcarbamylase Deficiency | Urea Cycle Disorders | Citrullinemia | Carbamoylphosphate Synthetase I DeficiencyGermany
-
West Kazakhstan Medical UniversityRecruitingOrnithine Transcarbamylase Deficiency | Biotinidase Deficiency | Citrullinemia | Glutaric Acidemia Type II | Argininosuccinic Aciduria | Maple Syrup Urine Disease | Primary Carnitine Deficiency | Homocystinuria | Carnitine Palmitoyltransferase II Deficiency | Arginase Deficiency | Very Long-chain Acyl-CoA... and other conditionsKazakhstan
-
University Hospital, Strasbourg, FranceUnknownThe Glutathione Synthetase DeficiencyFrance
-
Nicholas Ah MewIcahn School of Medicine at Mount Sinai; Boston Children's HospitalRecruitingN-acetylglutamate Synthase (NAGS) DeficiencyUnited States
-
The First Hospital of Jilin UniversityNational Natural Science Foundation of ChinaUnknownGenetic Diseases, Inborn | Asparagine Synthetase DeficiencyChina
-
National Human Genome Research Institute (NHGRI)TerminatedCitrullinemia | Argininosuccinic Aciduria | Hyperargininemia | Ornithine Carbamoyltransferase Deficiency | Carbamoyl-Phosphate Synthase I Deficiency | N-Acetylglutamate Synthase DeficiencyUnited States
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development...WithdrawnUrea Cycle Disorders, Inborn | Inborn Errors of Metabolism | Propionic Acidemia | Methylmalonic Acidemia | Carbamyl Phosphate Synthetase Deficiency
-
Baylor Research InstituteUltragenyx Pharmaceutical IncCompletedAdult Polyglucosan Body Disease | Glycogen Brancher Enzyme Deficiency | Glycogen Storage Disease Type IVFrance
-
Rigshospitalet, DenmarkUltragenyx Pharmaceutical IncCompletedTarui Disease | Debrancher Deficiency | GYG1 DEFICIENCYDenmark
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Pompe DiseaseUnited States
-
Heinrich-Heine University, DuesseldorfCompletedPeripheral Blood Mononuclear Cell | Red Blood Cell | Endothelial NO-synthaseGermany
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Duke UniversityKriya TherapeuticsRecruitingGlycogen Storage Disease VI | GLYCOGEN STORAGE DISEASE IXa1 | GLYCOGEN STORAGE DISEASE IXa2 | Glycogen Storage Disease IXB | Glycogen Storage Disease IXC | GSD 9 (All Subtypes) | GSD 6United States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
Jerry Vockley, MD, PhDUltragenyx Pharmaceutical IncNo longer availableBarth Syndrome | Mitochondrial Trifunctional Protein Deficiency | Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency | Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2) | Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency | Glycogen Storage Disorders | Pyruvate Carboxylase Deficiency... and other conditionsUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2Netherlands
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2France
-
Per Bendix JeppesenAarhus University Hospital; University of AarhusUnknown
-
University of East AngliaCompletedEicosapentaenoic Acid | Cardiovascular Physiological Phenomena | Endothelial Nitric Oxide Synthase | Docosahexaenoic Acid (All-Z Isomer)United Kingdom
-
United States Army Research Institute of Environmental...Completed
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase DeficiencyUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States, Israel, France, United Kingdom
-
Cliniques universitaires Saint-Luc- Université...UnknownGlucose 6 Phosphatase Deficiency | Glycogen Storage Disease Type IBelgium
-
University Medical Center GroningenUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Children's Memorial Health Institute, PolandDepartment of Internal Medicine, Hypertension and Vascular Diseases, The...Not yet recruitingGlucose 6 Phosphatase DeficiencyPoland
-
John MitchellCompletedGlycogen Storage Disease Type III | Glycogen Storage Disease Type IA | Glycogen Storage Disease Type IB | Glycogen Storage Disease Type 0Canada
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands, United States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Canada, Australia
-
Genzyme, a Sanofi CompanyTerminatedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Israel
-
Spark TherapeuticsActive, not recruitingLysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
-
Spark TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Italy, United Kingdom, Netherlands, France, Germany
-
CENTOGENE GmbH RostockWithdrawnFructose Metabolism, Inborn Errors | Glycogen Storage Disease Type II | Glycogen Storage Disease | Glycogen Storage Disease Type V | Glycogen Storage Disease Type I | Glycogen Storage Disease Type III | Glycogen Storage Disease Type VII | Glycogen Storage Disease Type IV | Glycogen Storage Disease Type... and other conditionsGermany, India, Sri Lanka
-
Helga EllingsgaardCompletedGlycogen DepletionDenmark
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
Genzyme, a Sanofi CompanyTerminatedGlycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)United States, Taiwan, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)United States, Netherlands, United Kingdom, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)France
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)United States, France, Canada, Netherlands, Australia
-
Genzyme, a Sanofi CompanyRecruitingPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Glycogenesis 2 Acid Maltase DeficiencyCroatia, United States, Italy, Belgium, Czechia
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
Javier Gonzalez, PhDMaastricht University; University of Newcastle Upon-Tyne; Sugar Nutrition, UKCompletedLiver and Muscle Glycogen Use During Exercise.United Kingdom
-
Sanguine BiosciencesTerminatedGlycogen Storage Disease Type IBUnited States